It was a very good day for Immucor (BLUD). After the close on Tuesday, the blood transfusion systems reported its third-quarter net income rose to $19.3 million, or 27 cents per share, from its year-ago earnings of $15 million, or 21 cents a share. Revenue jumped 17.3% to $67 million. Meanwhile, analysts had forecast a profit of 21 cents per share on revenue of $62.2 million.

In addition, BLUD affirmed that its revenue and earnings for fiscal 2008 will be in line with estimates released in May 2007. At the time, Immucor had forecast earnings of 92 cents to 96 cents a share and revenue in a range of $249 million to $257 million. The consensus estimate stands at 91 cents per share in net income on revenue of $245.7 million.

While off their highs for the day, the shares of BLUD have increased nearly 10% this afternoon. The stock has broken out of its sideways trading range of support at the 21 level and resistance at the 23 level. However, one concern is that the equity hasn't completely filled in its March 12 gap lower. For that, I think the stock would actually need a close above the 27 level site of former support.

In option trading, calls were the most active (though the stock doesn't see a lot of option trading). The April 22.50 call had 520 contracts trade, while the April 25 call traded 344 contracts. The May 22.50 call also had 595 contracts change hands. On the put side, the most active was the April 25 put, with 239 contracts changing hands.